CPEX's drug-delivery technology attractive to Footstar

A unit of Footstar Corp., a holding company, has agreed to acquire CPEX Pharmaceuticals for $76.6 million in cash. The bid is worth $27.25 a share--more than twice what it was a year ago as back-to-back quarterly profits helped fuel investor interest. CPEX focuses on what it calls a "drug delivery platform technology." Platform, of course, is a key word that implies it's not just a one-shot deal, but a model for a whole family of drug-delivery applications. This likely made CPEX more attractive.

According to CPEX, its technology helps guide pharmaceuticals through the skin, nose and eye. The company's first product is Testim, a gel for testosterone replacement therapy licensed to Auxilium Pharmaceuticals, which is marketing the product in the U.S. and Europe.

CPEX also has additional licensed application with Serenity Pharmaceuticals for Ser-120, a product candidate for treatment of nocturia, or excessive nighttime urination. Ser-120 uses the company's intranasal drug delivery technology and is currently in Phase III trials.

- here's a report in FierceBiotech
- read the story from Bloomberg
- get the fact sheet (PDF) describing CPEX's drug-delivery technology

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.